Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting

Peregrine Pharmaceuticals PPHM today is presenting data from a Phase II trial of Cotara in recurrent glioblastoma multiforme at an oral poster discussion at 5:00 PM CDT at the Annual Meeting of the American Society of Clinical Oncology. In 41 patients treated at first relapse with a single infusion of Cotara, interim median overall survival is 8.8 months (38 weeks). Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered as a single-infusion therapy directly into the tumor, destroying the tumor from the inside out, with minimal exposure to healthy tissue. "We know of no other recurrent GBM therapy that has achieved comparable median overall and long-term survival using a single administration of one drug and we are eager to meet with the FDA in the fourth quarter to determine the optimal registration pathway for our novel brain cancer therapy Cotara," said Steven W. King, president and chief executive officer of Peregrine. "Recurrent GBM is one of the most critical unmet medical needs as patients have limited treatment options. Additional therapeutic options with the potential for new combination regimens that extend patient survival are urgently needed. As a single-treatment approach showing promising signs of overall survival and a good safety profile to date, Cotara may offer advantages when administered alone or in combination with other therapies for patients with this deadliest form of brain cancer."